Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/2005
11/09/2005CN1694728A Cyclodextrin-based polymers for therapeutics delivery
11/09/2005CN1694727A Injections for eye tissue containing drug bound to polyethylene glycol
11/09/2005CN1694714A Formulation for inwardly transferring nucleic acids into eucaryotic cells
11/09/2005CN1692940A External-applied ointment used for treating thyropathy, and its prepn. method
11/09/2005CN1226332C Negatively charged amphiphilic block copolymer as drug carrier and complex thereof with positively charged drug
11/09/2005CN1226047C Pharmaceutical compositions
11/08/2005US6962982 Diagnosis of human immunodeficiency virus
11/08/2005US6962978 Multiple sclerosis; immobilization; water solubility
11/08/2005US6962944 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
11/08/2005US6962931 Oral bioavailability of a CETP inhibitor
11/08/2005US6962908 Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
11/08/2005US6962903 Modified annexin proteins and methods for preventing thrombosis
11/08/2005US6962900 Pharmaceutical being used for treating HIV infection, the composition and uses thereof
11/08/2005US6962784 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
11/08/2005US6962777 VLP-containing compositions produced express conformational, neutralizing epitopes and have high homogeneity and therefore comprise effective diagnostic and prophylactic agents for diagnosis or prevention of papillomavirus infections
11/08/2005US6962717 Pharmaceutical compositions
11/08/2005US6962711 Cosmetic and dermatological preparations comprising increased electrolyte concentrations
11/08/2005US6962703 Clostridial toxin derivatives able to modify peripheral sensory afferent functions
11/08/2005US6962694 Cytolysis of target cells by superantigen conjugates inducing T-cell activation
11/08/2005CA2382599C Flushable disposable polymeric products
11/08/2005CA2269501C Pellets having a core coated with an antifungal and a polymer
11/08/2005CA2193405C Eyewash intended in particular for the treatment of the dry eye syndrome
11/08/2005CA2149753C Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
11/08/2005CA2125685C Powders for inhalation and process for preparing them
11/06/2005CA2505836A1 Topical brimonidine tartrate formulations that lack chlorine dioxide
11/03/2005WO2005103263A1 Bone delivery conjugates and method of using same to target proteins to bone
11/03/2005WO2005103231A2 Dentritic cells charged with toxic substances in order to treat kidney cell carcinomas
11/03/2005WO2005103230A2 Soy peptone as a nitrogen source in preparing meningococcal conjugates
11/03/2005WO2005103087A1 Method for the purification of albumin conjugates
11/03/2005WO2005103081A2 Human monoclonal antibodies against cd20
11/03/2005WO2005103067A1 Methods and kits for stabilising, protecting and solubilising proteins
11/03/2005WO2005103041A2 Treatment of cns disorders using cns target modulators
11/03/2005WO2005102393A1 Patch for external use with elevated content of absorption promoter in pressure-sensitive adhesive base
11/03/2005WO2005102369A1 Pharmaceutical preparation containing bacterial cell wall skeleton component
11/03/2005WO2005102307A2 Beneficial effects of increasing local blood flow
11/03/2005WO2005102306A1 Anti-inflammatory analgesic adhesive patch
11/03/2005WO2005102295A1 Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens
11/03/2005WO2005102293A1 Poly (lactide-co-glycolide)-based sustained release microcapsules comprising a polypeptide and a sugar
11/03/2005WO2005102291A1 Seamless capsule containing water-soluble active ingredient
11/03/2005WO2005102288A2 Lozenge for delivery of dextromethorphan
11/03/2005WO2005102282A1 Transdermal delivery of beneficial substances effected by a hostile biophysical environment
11/03/2005WO2005102275A2 Galantamine salts, method of producing it and nasal composition thereof
11/03/2005WO2005102274A2 Method of stabilizing disordered cefovecin sodium salt
11/03/2005WO2005102269A2 An amine drug-containing slow-release granule preparation based on particles with a coating layer and the corresponding method of production
11/03/2005WO2005101993A2 Metal-containing nanolayered composites, and applications thereof
11/03/2005WO2005101982A2 A stable ophthalmic composition
11/03/2005WO2005084307A9 Use of lipid conjugates in the treatment of disease
11/03/2005WO2005071067A3 Non-animal origin stabilizers and processes for producing the same
11/03/2005WO2005061005A3 Branched polyethylene glycol for linking polymer residues to antibodies
11/03/2005WO2005016322A3 Pharmaceutical compositions of lavendustin
11/03/2005WO2004108070A3 Releasable polymeric conjugates based on aliphatic biodegradable linkers
11/03/2005WO2004093916A8 A medicament for the two-step perioperative therapy of solid tumours
11/03/2005WO2004089355A8 Compositions for treating microbial and parasitic infections in cattle and other animals
11/03/2005WO2004064811A8 A composition material for transmucosal delivery
11/03/2005WO2004014156A8 A chemical carrier based on a beta-limit dextrin
11/03/2005WO2003074551A8 Conjugates of therapeutic or cytotoxic agents and biologically active peptides
11/03/2005WO2003066000A3 Formulation comprising bioactive agents and method of using same
11/03/2005WO2003034980A8 A novel pharmaceutical compound containing abacavir sulfate and methods of making and using same
11/03/2005US20050245857 Device for electrochemotherapy
11/03/2005US20050245735 Neutral glycosphingolipids and glycosyl-sphingosines and methods for isolating the same
11/03/2005US20050245609 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
11/03/2005US20050245599 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
11/03/2005US20050245556 Pharmaceutical preparation containing oxycodone and naloxone
11/03/2005US20050245493 Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
11/03/2005US20050245492 Use of equol for treating skin diseases
11/03/2005US20050245483 Matrix for sustained, invariant and independent release of active compounds
11/03/2005US20050245468 Anthelmintic composition
11/03/2005US20050245455 Gonadotropin releasing hormone antagonists in gel-forming concentrations
11/03/2005US20050245445 Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
11/03/2005US20050245442 Androgens conjugated with mammalian proteins; diagnosis or treatment of solid cancer and hematological malignancies; exhibit synergistic action together with a cytoskeleton-acting drug; prostate cancer
11/03/2005US20050245439 Prevention of joint destruction
11/03/2005US20050244899 Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
11/03/2005US20050244884 Nucleotide sequence/polypeptide fusion for use as capture tool on solid supports during genomic analysis
11/03/2005US20050244812 Kits and methods for detection of apoptotic cells
11/03/2005US20050244522 Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents
11/03/2005US20050244519 Bulking agent compositions
11/03/2005US20050244514 Flavone and adenosine from Ixeris Sonchifolia Hance is more stable in the lyophilized powder form than in liquid form for injection so that it is easy to control the quality of the product so as to make the medicament safe and effective
11/03/2005US20050244509 Ophthalmic solutions
11/03/2005US20050244505 Immunotherapy compositions, method of making and method of use thereof
11/03/2005US20050244502 Composition for enhancing absorption of a drug and method
11/03/2005US20050244501 Water-soluble stabilized self-assembled polyelectrolytes
11/03/2005US20050244489 Liquid compositions for soft sustained-release capsules and method for production
11/03/2005US20050244488 Methods and formulations for enhansing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
11/03/2005US20050244485 Transdermal administration of hydrophilic drugs using a basic permeation enhancer composition
11/03/2005US20050244472 Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
11/03/2005US20050244469 Inserting an implant into an ocular site; an active agent and a polymer carrier; releasing the active agent from the implant
11/03/2005US20050244435 Comprises clostridial neurotoxin light chain domains; endopeptidases; vaccines; fusion proteins; for inhibiting exocytosis
11/03/2005US20050244425 Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
11/03/2005US20050244424 Carbohydrate-based synthetic vaccines for hiv
11/03/2005US20050244413 Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
11/03/2005US20050244395 Targeted enzyme prodrug therapy
11/03/2005US20050244370 Selective local activation of members of the TNF receptor family by systemically inactive non-antibody TNF ligand fusion proteins
11/03/2005US20050244341 Aerodynamically light particles for pulmonary drug delivery
11/03/2005US20050244340 Dry powder compositions
11/03/2005US20050241645 Composition for preventing the transmission of human immunodeficiency syndrome virus
11/03/2005DE102004017705A1 Ferromagnetische Kohlenstoff-Nanoröhren, die Biomoleküle tragen, Verfahren zu deren Herstellung und deren Verwendung in Diagnose und Therapie Ferromagnetic carbon nanotubes carrying biomolecules, processes for their preparation and their use in diagnosis and therapy
11/03/2005DE102004016355A1 Herstellung und Verwendung des Konjugats Methotrexat-Albumin als Mittel zur Immunosuppression bei GVHD Manufacture and use of the conjugate of methotrexate albumin as a means of immunosuppression in GVHD
11/03/2005DE102004011776A1 Trägersystem in Form von Nanopartikeln auf Proteinbasis zur zellspezifischen Anreicherung von pharmazeutisch aktiven Wirkstoffen Carrier system in the form of nanoparticles protein-based cell-specific enrichment of active pharmaceutical ingredients
11/03/2005DE102004009154A1 Novel combination of hexyl 2-(4-diethylamino-2-hydroxybenzoyl)-benzo ate and triheptylin is used as a light stabilizer especially in cosmetics or dermatological compositions
11/03/2005DE102004008017A1 Increasing nutrient bioavailability comprises administering a dietary supplement together with a galactomannan or glucomannan
1 ... 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 ... 1712